BUDGET IMPACT OF SELINEXOR COMBINATION REGIMENS IN PREVIOUSLY TREATED MULTIPLE MYELOMA

被引：0
|
作者：
Carter, J. A. [1 ]
Ijioma, S. [2 ]
Ray, D. [3 ]
机构：
[1] OPEN Hlth, Bethesda, MD USA
[2] Karyopharm Therapeut Inc, Marietta, GA USA
[3] Karyopharm Therapeut Inc, Newton, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE403
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [1] US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
    Dolph, Mike
    Tremblay, Gabriel
    Leong, Hoyee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 493 - 502
  • [2] Selinexor for the treatment of patients with previously treated multiple myeloma
    Mo, Clifton C.
    Jagannath, Sundar
    Chari, Ajai
    Nooka, Ajay K.
    Lonial, Sagar
    Siegel, David
    Biran, Noa
    Gasparetto, Cristina
    Bahlis, Nizar J.
    Richardson, Paul
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (08) : 697 - 706
  • [3] Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma
    Yahiya Y. Syed
    Targeted Oncology, 2023, 18 : 303 - 310
  • [4] US budget impact (BI) model for selinexor, bortezomib, and dexamethasone (XVd) for the treatment of patients with previously treated multiple myeloma (MM).
    Dolph, Mike
    Tremblay, Gabriel
    Leong, Hoyee
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2023, 18 (02) : 303 - 310
  • [6] US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
    Bassali, Jan
    Gould, Ian Gopal
    Kaye, James A.
    Mladsi, Deirdre
    Mehta, Jyotsna
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 317 - 325
  • [7] Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
    Mateos, Maria V.
    Gavriatopoulou, Maria
    Facon, Thierry
    Auner, Holger W.
    Leleu, Xavier
    Hajek, Roman
    Dimopoulos, Meletios A.
    Delimpasi, Sosana
    Simonova, Maryana
    Spicka, Ivan
    Pour, Ludek
    Kriachok, Iryna
    Pylypenko, Halyna
    Doronin, Vadim
    Usenko, Ganna
    Benjamin, Reuben
    Dolai, Tuphan K.
    Sinha, Dinesh K.
    Venner, Christopher P.
    Garg, Mamta
    Stevens, Don A.
    Quach, Hang
    Jagannath, Sundar
    Moreau, Philippe
    Levy, Moshe
    Badros, Ashraf Z.
    Anderson, Larry D., Jr.
    Bahlis, Nizar J.
    Cavo, Michele
    Chai, Yi
    Jeha, Jacqueline
    Arazy, Melina
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Richardson, Paul G.
    Grosicki, Sebastian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [8] Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
    Maria V. Mateos
    Maria Gavriatopoulou
    Thierry Facon
    Holger W. Auner
    Xavier Leleu
    Roman Hájek
    Meletios A. Dimopoulos
    Sosana Delimpasi
    Maryana Simonova
    Ivan Špička
    Ludĕk Pour
    Iryna Kriachok
    Halyna Pylypenko
    Vadim Doronin
    Ganna Usenko
    Reuben Benjamin
    Tuphan K. Dolai
    Dinesh K. Sinha
    Christopher P. Venner
    Mamta Garg
    Don A. Stevens
    Hang Quach
    Sundar Jagannath
    Philippe Moreau
    Moshe Levy
    Ashraf Z. Badros
    Larry D. Anderson
    Nizar J. Bahlis
    Michele Cavo
    Yi Chai
    Jacqueline Jeha
    Melina Arazy
    Jatin Shah
    Sharon Shacham
    Michael G. Kauffman
    Paul G. Richardson
    Sebastian Grosicki
    Journal of Hematology & Oncology, 14
  • [9] Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
    Schiller, Gary J.
    Lipe, Brea C.
    Bahlis, Nizar J.
    Tuchman, Sascha A.
    Bensinger, William I.
    Sutherland, Heather J.
    Lentzsch, Suzanne
    Baljevic, Muhamed
    White, Darrell
    Kotb, Rami
    Chen, Christine I.
    Rossi, Adriana
    Biran, Noa
    Leblanc, Richard
    Grosicki, Sebastian
    Martelli, Maurizio
    Gunsilius, Eberhard
    Spicka, Ivan
    Stevens, Don Ambrose
    Facon, Thierry
    Mesa, Mercedes Gironella
    Zhang, Chris
    Domelen, Dane R. Van
    Bentur, Ohad S.
    Gasparetto, Cristina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (09): : e286 - e296.e4
  • [10] A US BUDGET IMPACT MODEL FOR SELINEXOR IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Bassali, J.
    Gould, I
    Mladsi, D. D.
    Kaye, J. A.
    Shah, J.
    Mehta, J.
    VALUE IN HEALTH, 2020, 23 : S33 - S33
12345